The latest announcement: 7234 pharmaceutical manufacturers and 585,000 pharmacies

Medical Cloud Studio: Exploring the value in the trend

Total overseas production Drug License3874, of which 86 natural medicine, Chinese medicine, chemicals, 2767, 481 biological products, accessories 76 overseas production of pharmaceuticals sub-package 464 Jian

According to the "First Pharmacy Financial Intelligence", the total number of pharmacies in China, the number of chain enterprises, and the chain rate have all increased year by year during the 10 years from 2011 to 2021Q2

▲Image source: Caizhi of No.

At present, the competition between drugstore chains can be described as “hands-on-hand”, but in the first quarter of this year, the speed of domestic retail pharmacies opening remains unchanged, 7,000 more than last year

According to the "Associated Finance Press" report, the five leading domestic drugstores such as Dashenlin, Yifeng Pharmacy, People, Yixintang, and Jianzhijia, the top four listed pharmacies will all add more than 1,000 directly-operated stores in 2020.

As of the first quarter of 2021, the total number of end-of-period stores of Dashenlin, Yifeng Pharmacy, Lao People, Yixintang, and Jianzhijia reached 6451/6279/7268/7537/2216 respectively
.
Combined with the previous quarterly report, compared to the same period last year and the annual revenue growth rate, major pharmacies have seen a "downgrade" in revenue growth, but the gross profit margin has increased slightly
.

An insider from a drugstore chain company in southwestern China revealed to the "Associated Press" in a phone call that during the epidemic last year, more varieties were sold.
The increase in sales of anti-epidemic materials drove the growth of passenger flow and promoted the expansion of revenue.
The relative gross profit margin of this part of the product was low
.
Due to the large base in the same period last year, the sales growth rate will be different in the first quarter of this year, and the subsequent impact will gradually decrease.
The increase in gross profit margin is mainly due to the adjustment of sales product structure (lower gross-rate anti-epidemic product sales)
.
Sales remained stable in the second quarter, with no significant year-on-year fluctuations
.

Combining the industry boom and single-quarter performance, Southwest Securities Pharmaceutical Researcher Du Xiangyang believes that the overall performance growth rate of the retail pharmacy sector is expected to be between 20% and 30%, of which Dashenlin, Yifeng Pharmacy, and Yixintang are expected to grow at a rate of 25%-30%
.
Regarding this data, an expert who has been tracking the pharmacy industry for a long time told reporters that the net profit growth rate (in the first half of the year) is estimated to be similar, but the revenue growth rate will not be so high, which is estimated to be in the range of 10% to 20%
.

▲ Image source: Cailian Press

In addition to the slowdown in the revenue growth of the above-mentioned five top pharmacy chains, as far as the national pharmacy market is concerned, according to IQVIA data, the national retail pharmacy market in the first quarter of this year was 203.
2 billion yuan, and the sales of prefecture-level retail pharmacies year-on-year Down by 1.
4%
.

Behind the decrease in sales is that the number of stores is still increasing, which also means that there is "more porridge and less" in the market.
In order to compete for more passenger traffic, industry price wars are inevitable, and sales are bound to have an impact
.

The single passenger traffic and the amount of growth in the industry is the core driving force
.
Sub- analysis sources said that since February this year, the industry's traffic index has been less than 90, indicating that more than 10% of customer traffic can be shifted to other channels, while May retail pharmacies passenger traffic has been warmer, but the impact of electricity providers and hospitals reflux still affect Will exist for a long time
.

According to the research and analysis of IFC Securities, the overall performance of the pharmacy sector is under pressure.
It is expected that the growth rate in the second half of the year is expected to increase and maintain.
In the long term, it is optimistic that the increase in concentration and the outflow of prescriptions will bring certain growth to the leading pharmacies.
The sinking of prescriptions is expected to accelerate the rate of prescription outflow
.
Offline pharmacies are still expected to maintain a growth rate of more than 20% in 3-5 years
.

Basic situation of medical device manufacturing enterprises + operating enterprises

The report also shows that as of the end of June 2021, the country has a real medical equipment manufacturing enterprises 2.
75 Wan , of which:

There are 16,000 companies that can produce products of the first category, 13,600 companies that can produce products of the second category, and 2,122 companies that can produce products of the third category
.

As of the end of June 2021, the national real second, three types of medical equipment enterprises  99.
20 Wan , of which only the second class medical device products business enterprises 658 800, operating only Class III medical devices products company 82000 At the same time, there are 251,300 companies engaged in the operation of the second and third categories of medical devices
.

There are 375  companies that provide third-party platform services for medical device online transaction services  .

Approval status of Internet drug information service agencies

As of the end of June 2021, the provinces (autonomous regions and municipalities) approval of Internet drug information services  19924  Jia
.